US plans 100% tariffs on drugmakers without pricing deals to lower drug costs

The Trump administration is preparing to impose 100% tariffs on pharmaceutical companies that have not secured pricing agreements with the White House, as part of a national security investigation under the Trade Expansion Act. Major drugmakers like Pfizer, Eli Lilly, and Johnson & Johnson have already agreed to three-year pricing deals to avoid tariffs. This move is part of a broader strategy to reduce drug prices, including the TrumpRx.gov platform that helps consumers find discounted medications. The tariffs aim to push companies toward more affordable drug pricing amid growing public concern over healthcare costs in the US.